ADVANCE infectious diseases pharmacy through collaboration, research and education and LEAD antimicrobial stewardship to OPTIMIZE the care of patients with infections in every practice setting

Forgot password


COVID-19 Remdesivir Toolkit

SIDP has developed guidance documents pertaining to the use of remdesivir (Veklury®) for the treatment of COVID-19 for both outpatient and inpatient administration of 3 and 5 day regimens, informed by the experiences of pharmacists who have implemented remdesivir therapeutic regimens at their medical centers.

Toolkit Features:

    • Tools to guide patient selection, prioritization, and scheduling
    • Guides/ checklists on how to start a remdesivir infusion center/process for various infusion sites
    • Remdesivir compounding guidance
    • Education (Providers, Nurses, Patients)
    • Billing, reimbursement and access for remdesivir
    • Remdesivir availability

    SIDP member, Drew Zimmer, PharmD (left), discussing therapeutic options for COVID-19 with a colleague.

    Toolkit Contents

    Toolkit Contents are free for everyone! Register or sign-in to download and customize the documents (as needed). Follow the links below to access the toolkit documents.

    • Criteria for use

    • Considerations for starting processes

    • Compounding guidance

    • Provider Education
    • Nursing Education
    • Patient Education

    • Billing, reimbursement information, coding

    • Remdesivir is FDA approved and available commercially

    Access Toolkit Resources

    Sign-up as a Registered Resource User of this free content in order to access toolkit materials. Of note, this content is publicly available at no cost. SIDP membership is not required to register as a toolkit user.

    SIDP will not share any contact information provided with any third party and

    will only contact registered resource users with information pertaining to educational resources


    Once you have signed up as a Registered Resource User, access the toolkit resources using the link below! Note, SIDP members can also access the toolkit at the link below.

    Disclaimer

    Please keep in mind that information, data regarding COVID-19 therapeutics is constantly evolving. Use of SIDP guidelines and/or toolkits are intended as recommendations. Use does not supersede clinical judgement based on the assessment of an individual patient by an individual practitioner. The recommendations reflect the best available evidence at the time of publication and are not the sole resource for patient care management and/or an exclusive source of action.

    SIDP COVID-19 Remdesivir Toolkit Taskforce Members

    Special thanks to the following SIDP members for volunteering their time and efforts to the development of this toolkit:

      Authors

      • Sara Ausman
      • Esther Bae
      • Hita Bhagat
      • Christina Koutsari
      • Yosef Nissim
      • Natasha Pettit
      • Neda Pourdeyhimi

      Reviewers

      • Christina O'Connor
      • Drew Zimmer

        SIDP Member, Christina O'Connor, PharmD (left) discussing therapeutic options for COVID-19 with an advanced practice practitioner colleague.

        This toolkit was supported in part by Gilead Sciences, Inc. All content creation and peer review were conducted independently by SIDP members.

        Release Date 4/18/2023, Updated 4/18/2023


        Society of Infectious Diseases Pharmacists • PO Box 1488, Warrenville, IL 60555
        (331) 248-7888 • sidp@affinity-strategies.com
        Proudly Managed by Affinity Strategies

        Powered by Wild Apricot Membership Software